Public Alert No. 037/2023 – Alert on Substandard (contaminated) syrup and suspension medicines identified in the WHO Regions of the Americas, Eastern Mediterranean, South-East Asia and Western Pacific
The National Agency for Food and Drugs Administration and Control (NAFDAC) is notifying Healthcare providers and the general public of the WHO Medical Product Alert referring to five different Oral liquid dosage forms (syrup and suspension) detected in the Maldives and Pakistan. Some of the affected products have also been detected in Belize, Fiji and […]
Important Covid-19 Vaccine Safety Communication To Healthcare Providers
, Important Covid-19 Vaccine Safety Communication To Healthcare Providers KEY POINTS Possible Rare Event, Severe Allergic Reactions (Anaphylaxis) and Thromboembolic Events with Some Covid-19 Vaccines (probably due to underlying medical conditions and use of certain medications). Possible contraindications with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), especially Diclofenac with COVID-19 Vaccines NAFDAC maintains that authorised vaccines should continue […]
